IntegraGen SA (ALINT.PA)

EUR 0.53

(0.0%)

Net Income Summary of IntegraGen SA

  • IntegraGen SA's latest annual net income in 2023 was -171.39 Thousand EUR , down -4787.34% from previous year.
  • IntegraGen SA's latest quarterly net income in 2024 Q2 was -115 Thousand EUR , down 0.0% from previous quarter.
  • IntegraGen SA reported an annual net income of -3507.00 EUR in 2022, down -122.76% from previous year.
  • IntegraGen SA reported an annual net income of 15.4 Thousand EUR in 2021, up 104.11% from previous year.
  • IntegraGen SA reported a quarterly net income of -262.3 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
  • IntegraGen SA reported a quarterly net income of -171.39 Thousand EUR for 2023 FY, down -4787.34% from previous quarter.

Annual Net Income Chart of IntegraGen SA (2023 - 2008)

Historical Annual Net Income of IntegraGen SA (2023 - 2008)

Year Net Income Net Income Growth
2023 -171.39 Thousand EUR -4787.34%
2022 -3507.00 EUR -122.76%
2021 15.4 Thousand EUR 104.11%
2020 -375.02 Thousand EUR -31.59%
2019 -285 Thousand EUR 74.99%
2018 -1.13 Million EUR -32.19%
2017 -862.17 Thousand EUR 47.77%
2016 -1.65 Million EUR -7.62%
2015 -1.53 Million EUR -46.97%
2014 -1.04 Million EUR 59.0%
2013 -2.54 Million EUR -47.49%
2012 -1.72 Million EUR 15.4%
2011 -2.04 Million EUR 29.56%
2010 -2.89 Million EUR -5.95%
2009 -2.73 Million EUR 9.66%
2008 -3.02 Million EUR 0.0%

Peer Net Income Comparison of IntegraGen SA

Name Net Income Net Income Difference
ABIONYX Pharma SA -3.51 Million EUR 95.128%
ABIVAX Société Anonyme -147.74 Million EUR 99.884%
Adocia SA -21.16 Million EUR 99.19%
Aelis Farma SA -5.07 Million EUR 96.625%
Biophytis S.A. -17.02 Million EUR 98.993%
Advicenne S.A. -7.03 Million EUR 97.562%
genOway Société anonyme 1.56 Million EUR 110.934%
Medesis Pharma S.A. -3.95 Million EUR 95.671%
Neovacs S.A. -8.74 Million EUR 98.04%
NFL Biosciences SA -3.74 Million EUR 95.424%
Plant Advanced Technologies SA 79.16 Thousand EUR 316.498%
Quantum Genomics Société Anonyme -3.17 Million EUR 94.595%
Sensorion SA -22.06 Million EUR 99.223%
Theranexus Société Anonyme -6.82 Million EUR 97.49%
TME Pharma N.V. -6.73 Million EUR 97.455%
Valbiotis SA -7.36 Million EUR 97.674%
TheraVet SA -1.57 Million EUR 89.088%
Valerio Therapeutics Société anonyme -20.34 Million EUR 99.157%
argenx SE -272.91 Million EUR 99.937%
BioSenic S.A. -28.77 Million EUR 99.404%
Celyad Oncology SA -8.44 Million EUR 97.971%
DBV Technologies S.A. -67.26 Million EUR 99.745%
Galapagos NV 211.69 Million EUR 100.081%
Genfit S.A. -28.89 Million EUR 99.407%
GeNeuro SA -14.75 Million EUR 98.839%
Hyloris Pharmaceuticals SA -15.38 Million EUR 98.886%
Innate Pharma S.A. -7.57 Million EUR 97.736%
Inventiva S.A. -110.42 Million EUR 99.845%
MaaT Pharma SA -19.71 Million EUR 99.131%
MedinCell S.A. -25.03 Million EUR 99.315%
Nanobiotix S.A. -39.7 Million EUR 99.568%
Onward Medical N.V. -36.18 Million EUR 99.526%
Oryzon Genomics S.A. -3.35 Million EUR 94.888%
OSE Immunotherapeutics SA -23 Million EUR 99.255%
Oxurion NV -18.96 Million EUR 99.096%
Pharming Group N.V. -9.75 Million EUR 98.243%
Poxel S.A. -35.09 Million EUR 99.512%
GenSight Biologics S.A. -26.22 Million EUR 99.346%
Transgene SA -22.32 Million EUR 99.232%
Financière de Tubize SA 88.15 Million EUR 100.194%
UCB SA 343 Million EUR 100.05%
Valneva SE -101.42 Million EUR 99.831%
Vivoryon Therapeutics N.V. -28.34 Million EUR 99.395%